miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Martino, Maria Teresa Di; Arbitrio, Mariamena; Caracciolo, Daniele; Cordua, A.; Cuomo, O.; Grillone, Katia; Riillo, Caterina; Caridà, Giulio; Scionti, Francesca; Labanca, Caterina; Romeo, Caterina; Siciliano, Maria Anna; D’Apolito, Maria; Napoli, Cristina; Montesano, Martina; Farenza, Valentina; Uppolo, Valentina; Tafuni, Michele; Falcone, Federica; D’Aquino, Giuseppe; Calandruccio, Natale Daniele; Luciano, Francesco; Pensabene, Licia; Tagliaferri, Pierosandro; Tassone, Pierfrancesco

doi:10.1016/j.omtn.2022.02.005

Cited by 60 publications

(42 citation statements)

References 298 publications

(254 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure , the proposed dual-signal amplification strategy based on CHA and APE1 enzyme consists of three probes, including H 1 , H 2 , and MB. Previous studies have demonstrated that miR-221 is upregulated in various types of tumors . Therefore, miR-221 was chosen as the target model.…”

Section: Resultsmentioning

confidence: 99%

Dual-Signal Amplification Strategy Based on Catalytic Hairpin Assembly and APE1-Assisted Amplification for High-Contrast miRNA Imaging in Living Cells

Zhang,

Sun,

Xie

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

Early tumor diagnosis is crucial to successful treatment. Earlier studies have shown that microRNA is a biomarker for early tumor diagnosis. The development of highly sensitive miRNA detection methods, especially in living cells, plays an indispensable role for early diagnosis and treatment of tumor. Although the catalytic hairpin assembly (CHA)-based miRNA analysis strategy is commonly used for disease diagnosis, further application of CHA is hindered due to its low amplification efficiency and low tumor recognition contrast. To address these limitations, we propose a dual-signal amplification strategy based on CHA and APE1-assisted amplification, enabling highly sensitive and high-contrast miRNA imaging. The miR-221 was selected as a target model. This dual-signal amplification strategy has exhibited high amplification efficiency, which could analyze miRNA as low as 21 fM. This strategy also exhibited high specificity, which could distinguish target miRNA and nontarget with single-base differences. Moreover, this method showed significant potential for practical application, as it could successfully distinguish the expression difference of miR-221 in the plasma samples of normal people and patients. Most importantly, the expression level of the APE1 enzyme in tumor cells is higher than that in normal cells, allowing this strategy to sensitively and specifically image miRNA within tumor cells. This proposed method has also been successfully used to indicate fluctuations of intracellular miRNA and to distinguish miRNA expression between normal cells and cancer cells with high contrast. We anticipate that this method will provide fresh insights and can be a powerful tool for tumor diagnosis and treatment based on miRNA analysis.

show abstract

Section: Resultsmentioning

confidence: 99%

Dual-Signal Amplification Strategy Based on Catalytic Hairpin Assembly and APE1-Assisted Amplification for High-Contrast miRNA Imaging in Living Cells

Zhang,

Sun,

Xie

et al. 2024

Anal. Chem.

View full text Add to dashboard Cite

show abstract

“…Conflicting data regarding the oncogenic or tumor suppressive role of miR-221-3p in different cancers indicate its dual role in tumorigenesis [ 54 , 55 ]. In BC, high expression of miR-221-3p has been related to lymph node metastasis, distant metastasis, and poor prognosis [ 56 ].…”

Section: Discussionmentioning

confidence: 99%

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

Baldasici

Bălăcescu

Cruceriu

et al. 2022

IJMS

View full text Add to dashboard Cite

Neo-adjuvant therapy (NAT) is increasingly used in the clinic for the treatment of breast cancer (BC). Pathological response to NAT has been associated with improved patients’ survival; however, the current techniques employed for assessing the tumor response have significant limitations. Small EVs (sEVs)-encapsulated miRNAs have emerged as promising new biomarkers for diagnosis and prediction. Therefore, our study aims to explore the predictive value of these miRNAs for the pathological response to NAT in BC. By employing bioinformatic tools, we selected a set of miRNAs and evaluated their expression in plasma sEVs and BC biopsies. Twelve miRNAs were identified in sEVs, of which, miR-21-5p, 221-3p, 146a-5p and 26a-5p were significantly associated with the Miller–Payne (MP) pathological response to NAT. Moreover, miR-21-5p, 146a-5p, 26a-5p and miR-24-3p were independent as predictors of MP response to NAT. However, the expression of these miRNAs showed no correlation between sEVs and tissue samples, indicating that the mechanisms of miRNA sorting into sEVs still needs to be elucidated. Functional analysis of miRNA target genes and drug interactions revealed that candidate miRNAs and their targets, can be regulated by different NAT regimens. This evidence supports their role in governing the patients’ therapy response and highlights their potential use as prediction biomarkers.

show abstract

“…Numerous reports indicate that abnormalities in the expression of selected miRNAs may contribute to the transformation of glial cells and thus to the development of cancer. These include both miRNAs with suppressor and oncogenic functions ( Figure 2 ) [ 97 , 98 , 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 ].…”

Section: Mirnas Expression In Gbmmentioning

confidence: 99%

microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)—Recent Literature Review

Makowska

Smolarz

Romanowicz

2023

IJMS

View full text Add to dashboard Cite

Glioblastoma multiforme (GBM) is the most common, malignant, poorly promising primary brain tumor. GBM is characterized by an infiltrating growth nature, abundant vascularization, and a rapid and aggressive clinical course. For many years, the standard treatment of gliomas has invariably been surgical treatment supported by radio- and chemotherapy. Due to the location and significant resistance of gliomas to conventional therapies, the prognosis of glioblastoma patients is very poor and the cure rate is low. The search for new therapy targets and effective therapeutic tools for cancer treatment is a current challenge for medicine and science. microRNAs (miRNAs) play a key role in many cellular processes, such as growth, differentiation, cell division, apoptosis, and cell signaling. Their discovery was a breakthrough in the diagnosis and prognosis of many diseases. Understanding the structure of miRNAs may contribute to the understanding of the mechanisms of cellular regulation dependent on miRNA and the pathogenesis of diseases underlying these short non-coding RNAs, including glial brain tumors. This paper provides a detailed review of the latest reports on the relationship between changes in the expression of individual microRNAs and the formation and development of gliomas. The use of miRNAs in the treatment of this cancer is also discussed.

show abstract

miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review

Cited by 60 publications

References 298 publications

Dual-Signal Amplification Strategy Based on Catalytic Hairpin Assembly and APE1-Assisted Amplification for High-Contrast miRNA Imaging in Living Cells

Dual-Signal Amplification Strategy Based on Catalytic Hairpin Assembly and APE1-Assisted Amplification for High-Contrast miRNA Imaging in Living Cells

Circulating Small EVs miRNAs as Predictors of Pathological Response to Neo-Adjuvant Therapy in Breast Cancer Patients

microRNAs (miRNAs) in Glioblastoma Multiforme (GBM)—Recent Literature Review

Contact Info

Product

Resources

About